Burden of herpes zoster and postherpetic neuralgia: Incidence, proportion, and associated costs in the French population aged 50 or over;Évaluation de lincidence du zona, de la proportion des douleurs post-zostériennes, et des cots associés dans la population francaise de 50 ans ou plus

Revue d'Epidemiologie et de Sante Publique

Volumn 58, Issue 6, 2010, Pages 393-401

  Mick, G ^a   Gallais, J L ^b   Simon, F ^c   Pinchinat, S ^d   Bloch, K ^e   Beillat, M ^e   Serradell, L ^e   Derrough, T ^e  

^a HÔPITAL NEUROLOGIQUE   (France)

^b Societe Francaise de Medecine Generale   (France)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

^d Axonal Biostatem   (France)

^e SANOFI PASTEUR   (France)

Author keywords

Annual costs per disease; Epidemiology; Hespes zoster; Postherpetic neuralgia; Retrospective study

Indexed keywords

ADULT; AGE; ARTICLE; FEMALE; FRANCE; HEALTH CARE COST; HEALTH INSURANCE; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION RISK; MALE; POSTHERPETIC NEURALGIA; RETROSPECTIVE STUDY; SEX DIFFERENCE; COST; COST OF ILLNESS; ECONOMICS; MIDDLE AGED;

COST OF ILLNESS; COSTS AND COST ANALYSIS; FEMALE; FRANCE; HERPES ZOSTER; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; RETROSPECTIVE STUDIES;

EID: 78650005634     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respe.2010.06.166     Document Type: Article

References (48)

1. Thiry N., Beutels P., Shkedy Z., Vranckx R., Vandermeulen C., Van Der Wielen M., et al. The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 2002, 161:588-593.
2. Guidelines for the management of shingles: report of a working group of the British Society for the Study Infection. J Infect 1995, 30:193-200. British Society for the Study of Infection.
3. Gross G., Schöfer H., Wassilew S.W., Friese K., Timm A., Guthoff R., et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 2003, 26:277-289.
4. Lee V.K., Simpkins L., Herpes Zoster Postherpetic neuralgia in the elderly. Geriatr Nurs 2000, 21:132-136.
5. Edmunds W.J, Brisson M., Rose J.D. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001, 19:3076-3090.
6. Paul E., Thiel T. Epidemiology of varicella zoster infection. Results of a prospective study in the Ansbach area. Hautarzt 1996, 47(8):9-604.
7. Helgason S., Sigurdsson J.A., Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 1996, 2:12-16.
8. Brisson M., Edmunds W.J. Epidemiology of varicella zoster virus in England and Wales. J Med Virol 2003, 70:S9-S14.
9. Hope-Simpson E.R. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R 1965, 58:9-12.
10. Fleming D.M., Cross K.W., Cobb W.A., Chapman R.S. Gender difference in the incidence of shingles. Epidemiol Infect 2003, 132:1-5.
11. Chidiac C., Bruxelle J., Daurès J.P., Hoang-Xuan T., Morel P., Leplège A., et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001, 33:62-69.
12. Czernichow S., Dupuy A., Flahault A., Chosidow O. Zona: enquête d'incidence chez les médecins généralistes du réseau « en Sentinelles ». Ann Dermatol Venereol 2001, 128:497-501.
13. Di Luzio Paparatti U., Arpinelli F., Visonà G. Herpes zoster and its complications in Italy: an observational survey. J Infect 1999, 38:116-120.
14. Hope-Simpson R.E. Postherpetic neuralgia. J R Coll Gen Pract 1975, 25:571-575.
15. Opstelten W., Mauritz J.W., De Wit N.J., Van Wijck A.J.M., Stalman W.A.B., Van Essen G.A. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002, 19(No. 5):471-475.
16. Ragozzino M.W., Melton L.J., Kurland L.T., Chu C.P., Perry H.O. Population-based study of herpes zoster and its sequelae. Medicine 1982, 61:310-316.
17. Meister W., Neiss A., Gross G., Doerr H.W., Höbel W., Malin J.P., et al. Demography, symptomatology, and course of disease in ambulatory zoster patients. Intervirology 1998, 41:272-277.
18. Gauthier A., Breuer J., Carrington D., Martin M., Rémy V. Epidemiology and cost of herpes zoster and postherpetic neuralgia in the United Kingdom. Epidemiol Infect 2008, 1-10.
19. Schiffner-Rohe V.J., Jow S., Lilie H.M., Köster I., Schubert I. Herpes Zoster in Deutschland. MMW-Fortschritte der Medizin Originalien Nr 2009, 4:193-197.
20. Hanslik T., Blanchon T., Alvarez F.P. Immunization of adults against varicella and herpes zoster. Revue Med Int 2007, 28:166-172.
21. Hannouche D., Alfandari S., Bouhour D., Fouchard N., Geffray L., Quinet B. Prise en charge des infections à VZV. Med Mal Infect 1998, 28:1-8.
22. Johnson R.W., McElhaney J. Postherpetic neuralgia in the elderly. Int J Clin Pract 2009, 63:1386-1391.
23. Meister W., Neib A., Gross G., Doerr H.W., Höbel W., Malin J.P., et al. A prognostic score for postherpetic neuralgia in ambulatory patients. Infection 1998, 26. 359-13-363/17.
24. Dworkin R.H., Portenoy R.K. Proposed classification of Herpes Zoster pain. Lancet 1994, 343(8913):1648.
25. Thoughts on the definition of postherpetic pain: the time criterion adds nothing. Rev Neurol 2004, 160:721-725. Groupe d'Experts Douleurs Neuropathiques.
26. Volpi A., Gatti A., Pica F., Bellino S., Marsella L.T., Sabato A.F. Clinical and psychosocial correlates of postherpetic neuralgia. J Med Virol 2008, 80:1646-1652.
27. McKendrick M.W., Ogan P., Care C.C. A 9-year follow-up of postherpetic neuralgia and predisposing factors in elderly patients following herpes zoster. J Infect 2009, 59:416-420.
28. Schmader K.E. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002, 18:350-354.
29. Volpi A., Gross G., Hercogova J., Johnson R.W. Current management of herpes zoster: the European view. Am J Clin Dermatol 2005, 6:317-325.
30. NHS Quality Improvement Scotland. Evidence Note 21: Antiviral treatment for shingles and its complications in immunocompetent adults. 2008.
31. Li Q., Chen N., Yang J., Zhou M., Zhou D., Zhang Q., et al. Antiviral treatment for preventing postherpetic neuralgia. The Cochrane Collaboration 2009, John Wiley and Sons, Ltd.
32. Czernichow S., Flahault A., Dupuy A., Chosidow O. Douleurs postzostériennes: concernent 25 % des zona au-delà de 50 ans. Quotidien Med 1999, 6574:16.
33. Brisson M., Edmunds W.J., Law B., Gay N.J., Wall R., Brownell M., et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001, 127:305-314.
34. Seventer R.V., Sadosky A., Lucero M., Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006, 35:132-137.
35. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284.
36. Réseau Sentinelles. Bilan annuel du réseau Sentinelles - Bilan annuel 2007: Zona. 2007:71-6.
37. Sanchez-Ponton A., Serradell L., Papoz L., Pedalino B., Beillat M., Baptiste C., et al. Recrutement de l'étude EPIZOD: épidémiologie du zona et des douleurs post-zostériennes (méthode d'échantillonnage et de recrutement des médecins). Rev Epidemiol Sante Publique 2007, 55:16.
38. Wood A.J.J. Postherpetic neuralgia-pathogenesis, treatment and prevention. N Engl J Med 1996, 335:32-41.
39. Thomas S.L., Hall A.J. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 2004, 4:26-33.
40. Pérez-Faérinos N., Ordobas M., Garcia-Fernandez C., Garcia-Comas L., Canellas S., Rodero I., et al. Varicella and herpes zoster in Madrid, based on the sentinel general practitioner network: 1997-2004. BMC Infect Dis 2007, 7:1-5.
41. Yawn B.P., Saddier P., Wollan P.C., Sauver J.L., Kurland M.J., SY L.S. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 82:1341-1349.
42. Dworkin R.H., Carrington D., Cunningham A., Kost R.G., Levin M.J., McKendrick M.W., et al. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antivir Res 1997, 33:73-85.
43. Johnson R.W. Herpes Zoster in the immunocompetent patient: management of postherpetic neuralgia. Herpes 2003, 10:38-45.
44. Blanchon T., Alvarez F., Hanslik T., Dorléans Y., Turbelin C. Epidémiologie du zona et des névralgies post-zostériennes en France. Sentiweb-hebdo 2007, 12:1.
45. Scott F.T., Leedham-Green M.E., Barrett-Muir W.Y., Hawrami K., Gallagher W.J., Johnson R., et al. A study of shingles and the development of postherpetic neuralgia in east London. J Med Virol 2003, 70:S24-S30.
46. Gershon A.A. Epidemiology and management of postherpetic neuralgia. Semin Dermatol 1996, 15:8-13.
47. Chidiac C., Senneville E., Guéry B., Peixoto O. Prise en charge du zona en pratique de ville en 1996: résultats d'une enquête nationale. Med Mal Infect 1997, 27:810-817.
48. Scott F.T., Johnson R.W., Leedham-Green M.E., Davies E., Edmunds W.J., Breuer J. The burden of Herpes Zoster: a prospective population based study. Vaccine 2006, 24:1308-1314.